Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Critical Breathes Easier After Finding Promotion Partner For Pending Asthma Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal with Merck KGaA subsidiary DEY for zileuton CR adds more than 200 reps and expertise in detailing to respiratory physicians.

You may also be interested in...

FDA Asks Genentech To Add Boxed Anaphylaxis Warning To Xolair Label

Continued post-marketing reports of anaphylaxis, some well after treatment, led agency to ask for label revision.

Critical Therapeutics Seeks Co-Promotion Partner For Zileuton CR

The company will downsize Zyflo sales force ahead of expected approval of twice-daily zileuton for asthma.

Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts